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Abstract: Concentrations down to 3 nM of the rhS100A4 protein, associated with human 
tumor development, have been detected in undiluted urine using an integrated sensor based on 
microring resonators in the emerging Al2O3 photonic platform. The fabricated microrings 
were designed for operation in the C-band (λ = 1565 nm) and exhibited a high-quality factor 
in air of 3.2 × 105. The bulk refractive index sensitivity of the devices was ~100 nm/RIU (for 
TM polarization) with a limit of detection of ~10−6 RIU. A surface functionalization protocol 
was developed to allow for the selective binding of the monoclonal antibodies designed to 
capture the target biomarker to the surface of the Al2O3 microrings. The detection of 
rhS100A4 proteins at clinically relevant concentrations in urine is a big milestone towards the 
use of biosensors for the screening and early diagnosis of different cancers. Biosensors based 
on this microring technology can lead to portable, multiplexed and easy-to-use point of care 
devices. 
© 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement 
1. Introduction 
Early diagnostic of diseases will permit treatment before symptoms emerge, greatly 
increasing the survival rate and the quality of life of patients. In particular, screening for 
different types of cancer will help reducing the impact of this disease, which is one of the 
main causes of death in developed countries [1]. The monitoring of the pre- and post-
operative evolution of cancer patients is also of major significance. The S100 proteins family 
is associated with a regulatory role in a variety of cellular processes [2]. Many lines of 
investigation suggest that overexpression of S100 proteins is associated with tumor 
progression and prognosis [3,4]. S100A4 is a member of this family and it is found as a 
highly expressed transcript in metastatic tumor cell lines. S100A4 is up-regulated in several 
malignancies including bladder cancer and plays a role in tumor aggressiveness [5–7]. 
Therefore, the overexpression of S100A4 protein may be of value as a biomarker of bladder 
cancer progression. Urine levels of S100A4 for bladder cancer are not reported in the 
literature but Turnier et al. showed median urine levels of S100A4 around 0.1 nM for healthy 
controls and median urine levels ranging from 0.5 to 1 nM for patients with lupus nephritis 
using a commercially available ELISA kit [8]. 
At present, there are several commercial assays for bladder cancer diagnosis based on 
immunoassays, but they have high variability of sensitivity and specificity. In addition, in 
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most of them the false-positive rate is quite high, they require tedious/laborious assay 
procedures, are time consuming, expensive and need specialized personnel [9,10]. To this 
aim, the development of portable, low cost, multiplexed and easy to use devices that, within 
minutes, can detect cancer biomarkers directly from biofluids is instrumental. 
Integrated optical sensors are good candidates for the label-free detection of molecular 
biomarkers [11–13]. Microring resonator (MRR) based biosensors have shown high 
sensitivity and limit of detection compatible with clinical relevant needs [14,15]. Their 
operation is based on the wavelength shift of the narrow dips in their transmission spectrum 
induced by variations of the refractive index probed by the evanescent field. When their 
surfaces are functionalized with capture probes and biomarkers are bound to them, such 
binding induces refractive index changes that result in detectable wavelength shifts that can 
be used for biosensing. Limits of detection (LOD) around 10−6 RIU (refractive index units) 
are typically achieved using integrated MRR sensors [16,17]. The LOD is limited by the noise 
of the system due to temperature fluctuations and laser wavelength or intensity variations 
[18]. Label-free detection of biomarkers using MRRs has been demonstrated in different 
integrated photonic platforms, including silicon-on-insulator (SOI) [19–21], silicon oxynitride 
[22] and silicon nitride [23]. However, biological samples, such as blood, urine or saliva, are 
complex matrices that must be properly processed to remove interfering substances (proteins, 
metabolites). That pre-treatment is a tedious and critical step and it is not conducive to on-line 
processing and automation. In addition, the concentration of the biomarkers in clinical 
samples is often at nanomolar level or lower, and most of these references use amplification 
strategies to achieve clinically relevant LOD, which add a complexity to the system, 
associated to non-label free strategies [24–26]. 
Label-free detection of cancer biomarkers from buffer samples containing fetal bovine 
serum at a detection limit of 25 ng/ml was reported by Washburn et. al. with MRRs based on 
SOI technology [27]. More recently, Shin. et. al. realized label-free detection of bladder 
cancer DNA biomarkers from urine, although at quite high concentrations in the µM range, 
which are not useful for monitoring or early diagnostics [28]. To use MRR as sensitive and 
selective biosensors for clinical samples with good LOD, requires efficient functionalization 
strategies that allow anchoring the capture probes on the surface to selectively recognize the 
biomarker of interest. 
Aluminum oxide (Al2O3) is an emerging photonic material that, unlike the silicon-based 
technologies, has not been explored yet for biosensing applications. It has attractive features 
such as a low waveguide propagation loss down to 0.21 ± 0.05 dB/cm at a wavelength of 
1550 nm [29] and a large transparency window ranging from the visible to the mid-infrared 
[30], exceeding that of SOI and making this material very interesting for the realization of 
optical sensors working in the visible, near and mid-infrared wavelength ranges. Furthermore, 
this material has the possibility of being doped with rare earth ions to achieve optical gain and 
active functionalities [31–34]. This feature allows for the development of laser-based 
biosensors to achieve narrower linewidths, higher sensitivities and novel sensing 
functionalities [35,36]. However, the only reports of optical sensors using the Al2O3 photonic 
platform are the realization of a dual-wavelength Al2O3 distributed feedback laser whose 
evanescent field was used to detect the presence of glass microspheres of diameters ranging 
between 1 µm and 20 µm [37] and the usage of an Al2O3:Yb
3+ microdisk laser integrated on 
chip and operating in an aqueous environment to detect minute bulk refractive index 
variations [38]. Furthermore, high quality factor (Q) undoped Al2O3 MRRs were recently 
demonstrated by Su et al. [39], although they were not utilized for biosensing applications. 
The work presented here serves as a validation of using the undoped Al2O3 material platform 
for optical biosensors, with the prospects of expanding this platform by including dopants for 
active sensing functionalities. 
In this work, we demonstrate the development of MRR biosensors based on the Al2O3 
photonic platform with high sensitivity and low limit of detection. First, the MRR devices 
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were fully characterized, including their bulk refractive index and temperature sensitivity 
[40]. Performance on par with the silicon-based technologies is demonstrated. Then, the 
devices were tested for the detection of the rhS100A4 protein biomarker in undiluted urine. A 
limit of detection of 3 nM (~36 ng/ml) was demonstrated. This value lies within the clinically 
relevant range demonstrated by Turnier et al. for patients with lupus nephritis and can be used 
as a reference value for patients with bladder cancer [8,41,42]. These results show the 
potential of using this novel material platform to detect biomarkers in point-of-care 
applications using patients’ urine without any sample pre-treatment and/or complicated 
amplification steps. 
2. Sensor platform design and fabrication 
Waveguide MRRs were developed as biosensors on the Al2O3 material platform. Their 
wavelength dependent transmission spectra contain multiple resonance wavelengths 
whenever light inside the MRR has a roundtrip phase multiple of 2π (i.e., the resonance 
condition). Upon a variation of the refractive index of the environment of the MRR, the total 
roundtrip phase changes and the resonance wavelength shifts. By monitoring this shift, the 









where λ is the resonance wavelength of the MRR, ng is the group index of the waveguide, neff 
is the effective refractive index of the waveguide and n is the refractive index of the medium 
surrounding the waveguide. To ensure a high sensitivity, the derivative in Eq. (1) should be as 
high as possible, which can be realized by a waveguide design that has a large evanescent tail 
in the top cladding or, alternatively, by engineering the waveguide dispersion to reduce the 
group index [44]. 
Associated with the bulk refractive index sensitivity is the limit of detection (LOD). It 
characterizes the smallest variation of bulk refractive index that can still be reliably measured 





ε=  (2) 
where ε is the uncertainty or signal noise in the determination of the resonance wavelength. 
The uncertainty scales with the width of the resonance, i.e., its Q. Optimal sensing 
performance requires a low LOD, and thus a high S and low ε. However, extending the 
evanescent tail to increase the sensitivity can result in decreased Q due to increased bend 
radiation loss and absorption losses in the sensing medium, constraining the MRR waveguide 
design. 
The Al2O3 MRRs were designed to operate for both TE and TM polarization in the 
telecom band (λ = 1565 nm) to demonstrate compatibility with the widely available 
instrumentation used by the SOI platform. Furthermore, the waveguide should support only a 
single mode for both polarizations to avoid higher-order resonances in the transmission 
spectrum that would complicate the analysis and resonance wavelength monitoring. Finally, 
the MRRs are designed to be critically coupled and to exhibit high Q to ensure deep, sharp 
dips that will ease their curve fitting and reduce the noise in the extraction of the sensor 
parameters. 
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Fig. 1. (a) Mode profile of the fundamental mode for respectively TE polarization (I) and TM 
polarization (II). (b) Scanning electron microscope image of the Al2O3 waveguide cross 
section. (c) Optical microscope image of the MRRs inside the PDMS microfluidic flow 
channel. 
The MRR was modelled using a combination of an analytical MRR model with a 
numerical waveguide solver [45] to determine its geometric parameters. Fully vectorial 2D 
eigenmode calculations (Lumerical MODE solutions) were performed to determine the bend 
radiation loss, the power coupling from the bus waveguide to the MRR, and the S at a central 
wavelength of 1565 nm. At this wavelength, the bottom SiO2 cladding, the Al2O3 waveguide 
core material and the water top cladding have refractive indices of 1.46, 1.65 and 1.33 RIU, 
respectively. The optimum parameters for the MRR were determined to be a waveguide cross 
section of 2.0 × 0.7 µm2 for both the bus and MRR waveguide, a coupling gap of 0.8 µm, and 
a MRR radius of 200 µm. Figures 1(a) and 1(b) show the designed waveguide cross section 
with the dominant component of the modal field for respectively TE and TM polarization. 
These design parameters were used for the MRR fabrication. First, a 700-nm-thick Al2O3 
layer was deposited by reactive sputter deposition on an oxidized silicon substrate (i.e., 
thickness of thermal oxide of 8 μm) with an AJA ATC 1500 sputter coater. Then, the bus 
waveguides and MRRs were patterned with contact UV lithography and subsequently etched 
with an Oxford Plasmalab System 100 inductively coupled plasma reactive ion etcher with a 
plasma of BCl3 and HBr at a ratio of 5:2. Figure 1(b) displays the resulting waveguide cross 
section. A SiO2 top cladding was then locally deposited with PECVD using a shadow mask to 
cover the bus waveguide while leaving the MRRs exposed to address them with an aqueous 
environment. Finally, a PDMS microfluidic device with a 600 µm wide and 70 µm high 
channel, shown in Fig. 1(c), was bonded onto diced, cleaned and chemically activated chips 
containing the MRRs. 
3. Experimental 
3.1. MRR characterization set up 
To optically characterize the Al2O3 MRRs, an optofluidic experimental set up was developed 
and is shown in Fig. 2(a). The MRR chip was placed on the sample holder by vacuum 
connection. A Peltier driven temperature controller was used to drive the temperature of the 
sample holder within ~ ± 0.01°C. Laser light from an Agilent 81646 tunable laser was guided 
through single mode polarization maintaining fibers (PM1550-XP, mode field diameter of 
10.1 µm) and butt coupled to the chip’s end facets using index-matching fluid. For alignment 
of the fibers to the chip, a piezo-controlled micropositioner was used. To perform the 
alignment procedure, a red Helium-Neon (HeNe) laser was coupled into the device, as can be 
seen in Fig. 2(b). Finally, a syringe pump was connected to the PDMS microfluidic chip and 
used to flow liquid samples over the MRRs. 
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Fig. 2. (a) Photograph of the optofluidic chip mounted on the experimental setup. The chip has 
dimensions of 1.2 × 1.9 cm2. (b) Optical microscope image of the MRR and bus waveguide 
upon coupling red light from a HeNe laser into the device. 
Wavelength dependent transmission spectra of the MRRs were measured. For all 
following experiments, this was done at a rate of ~7 spectra per minute. The polarization was 
controlled by the fiber alignment. The transmission spectra were obtained for TE and TM 
polarized light for either a top cladding of air or while being submerged in H2O. The 
wavelength range was between λ = 1545 and 1570 nm with a resolution of 1 pm. To extract 
the propagation loss and resonance quality factor Q, the resonance peaks were fitted with a 
Lorentzian function to extract the MRR loss and coupling coefficients [46]. For the sensing 
experiments, the location of the resonance wavelength was extracted from repeatedly 
acquired transmission spectra over time for enhanced precision and reduced noise. 
The sensing performance of the MRR is characterized by measuring its bulk refractive 
index sensitivity and temperature sensitivity for both TE and TM polarized light. To 
determine the bulk refractive index sensitivity, deionized water and NaCl solutions were 
flown over the device. By increasing the concentration of NaCl, the refractive index of the 
deionized water can be varied by 0.0018 RIU/wt% [47]. Solutions with NaCl concentrations 
ranging from 0.05 wt% to 0.30 wt% were prepared and flown over the MRRs at a rate of 100 
µl/min, while simultaneously recording the transmission spectra to monitor the shift of the 
resonance wavelength. The stage temperature was kept fixed at 21.5°C. To determine the 
temperature sensitivity, the resonance wavelength shift was measured upon varying the 
temperature of the stage while immersing the MRR in deionized water at a flow rate of 10 
µl/min. The temperature was increased in steps of ~0.5°C every 4 minutes. 
3.2. Biosensing protocol 
Recombinant human S100A4 (rhS100A4) protein was obtained as described by [48]. 
Hybridoma obtaining and cell subcloning was performed using standard technologies. 
Briefly, mice were immunized with hrS100A4 and B cells were fused with myeloma cells to 
obtain hybridoma cells. After cell subcloning, serum free supernatant of the selected 
antibody-secreting hybridoma cell line was obtained and purified using protein A columns 
(MabSelect SureTM LX; Amersham) and an ÄKTA purifier FPLC system (GE Healthcare). 
For the sensitive and selective detection of biomolecules, a robust protocol for the 
covalent binding of the capture antibodies (Ab) to the Al2O3 surface was developed in our 
laboratory. Briefly, the Al2O3 surface was activated with O2 plasma and a carboxylic acid-
terminated layer was deposited. After the activation of the carboxylic terminals by an 
EDC/NHS reaction the MRR chips are ready for anchoring the capture antibody on its 
surface. The surface functionalization process developed permitted the preferential binding of 
antibodies to the Al2O3 material. Molecular recognition reactions would then guarantee that 
rhS100A4 proteins contained in the sample would bind to the surface immobilized antibodies 
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selectively. Figure 3(a) shows a schematic outline of the procedure used to functionalize the 
surface of the MRR. First, the MRR chip was cleaned with deionized water, acetone and 
ethanol to remove organic surface contaminants. Afterwards, to activate the surface for 
functionalization, the chip was cleaned with HNO3 and O2 plasma. After O2 plasma 
activation, the surface was modified with 6-phosphonohexanoic acid (500 µM, anhydrous 
heptane) and, after solvent evaporation, it was heated in an oven at 120°C for 12 hours to 
form a carboxylic acid-terminated layer. For Ab immobilization, the chip was immersed in a 
carboxylic acid activating solution (1-Ethyl-3-(3 dimethylaminopropyl)carbodiimide (EDC) 
25 mM, N-Hydroxysuccinimide (NHS) 50 mM, in 100 mM MES buffer, pH 4.7) for 2 hours, 
and gently washed with deionized water. To test the successful immobilization of antibodies 
on the surface, a fluorescence assay was carried out with an antibody labelled with 
fluorescein isothiocyanate fluorescence dye (10 µg/ml), as shown in Fig. 3(b). 
The PDMS microfluidic channel was bonded to the chemically functionalized MRRs and 
the flow rate was set at 100 µl/min. First, a solution containing Anti-S100A4 antibody at 50 
µg/ml in phosphate buffered saline (PBS) 10 mM was delivered until the reading signal was 
saturated, therefore indicating that a layer of capture probes was formed on the chemically 
functionalized surfaces. Then, a solution of bovine serum albumin (BSA) 1% in PBS 10 mM 
was flown to prevent nonspecific biomolecule adsorption. 
A urine sample was pooled from six healthy women. A 10 v/v% of PBS 100 mM was 
added to this urine, and the pH was adjusted to 7.5 by adding NaOH. Pooled urine samples 
were filtered with a 0.2 μm pore filter and stored at 4°C before use. Then, different amounts 
of the rhS100A4 protein were added to the urine samples to obtain samples spiked with 
known biomarker concentrations ranging from 3000 nM down to 3 nM. These samples were 
then flown over the biosensor at 100 µl/min for 10 min and the sensor response was 
monitored on-line. During the biosensing experiments the stage temperature was kept fixed at 
21.5°C. 
 
Fig. 3. (a) Schematic representation showing the developed Al2O3 surface functionalization 
protocol. (i) Surface activation with O2 plasma. (ii) 6-phosphonohexanoic acid, 500 µM in 
anhydrous heptane, reacts with the Al2O3 surface to generate a carboxylic acid-terminated 
surface. (iii) Activation of carboxylic terminals by EDC/NHS and anti-S100A4 antibody 
immobilization. (iv) Protein recognition. (b) (i) Schematic representation of the fluorescence 
assay to verify the immobilization of antibody capture probes. (ii) Microscope fluorescent 
image of Al2O3 ring functionalized with 6-phosphonohexanoic acid and immobilized with an 
antibody labelled with fluorescein isothiocyanate fluorescence dye (FITC, 495 nm/519 nm 
excitation/emission). Magnification 40x, acquisition time 2000 ms. 
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4. Results and discussion 
4.1. MRR characterization 
Wavelength-dependent transmission spectra of the Al2O3 MRRs were obtained for the TE and 
TM polarizations for both claddings of air and deionized water. Figures 4(a) and 4(b) show 
the sharp, deep resonance peaks present in the transmission spectra. The data was normalized 
by subtracting the background fitted by a high-order polynomial, followed by fitting the 
resonance peaks with a Lorentzian function. From the fit, the extinction ratio and full width 
half maximum were obtained, which were used to retrieve the waveguide propagation loss 
and loaded quality factors. 
A high quality factor and low optical loss inside the MRR are necessary for optimal 
sensing performance. Various repetitions of the design parameters were fabricated on the 
chips and measured. Out of them, the MRR design with the best performance was selected for 
the sensitivity and biosensing experiments. For this optimal MRR a loaded quality factor of Q 
= 3.2 ± 0.2 × 105 was found for TE polarization with an air cladding, corresponding with an 
optical propagation loss of 0.60 ± 0.04 dB/cm. For TM polarization with an air cladding, a Q 
of 9.6 ± 0.5 × 104 together with an optical loss of 2.00 ± 0.19 dB/cm were measured. The 
increased loss is due to the lesser confinement of the mode for TM polarization, exhibiting 
therefore higher bend and sidewall radiation loss. Since the devices were nearly critically 
coupled, these results would correspond with a highest intrinsic quality factor Qi ~6 × 10
5, a 
value similar as found by Su et al. [39]. However, an advantage of the Al2O3 MRRs presented 
here is that the fabrication process is simpler and requires only a single deposition and etching 
step. Furthermore, in principle the Q could be further increased by making the MRR 
waveguide both wider and thicker, to reduce the bend radiation loss and decrease the modal 
overlap with the sidewall roughness. However, this would come at the expense of reduced 
sensitivity and multimodal operation. 
 
Fig. 4. (a) MRR transmission spectrum for TE polarized light and a top cladding of air. (b) 
Lorentzian fit of one of the resonances in (a). 
The Q and optical loss analysis of the MRRs was repeated for a cladding of deionized 
water. Then, the Q dropped for both the TE and TM polarization, due to the optical 
absorption of the water in this wavelength range. The Qs were determined at 5.6 × 104 and 4.4 
× 104 for TE and TM polarization respectively, corresponding with optical propagation losses 
of 4.0 ± 0.6 and 5.7 ± 0.7 dB/cm, respectively. These results are summarized in Table 1. 
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Table 1. Summary of Al2O3 MRR optical loss. 
 Air  Deionized water 
Polarization Q (-) α (dB/cm)  Q (-) α (dB/cm) 
TE 
3.2 ± 0.2 × 
105 0.60 ± 0.04  5.9 ± 8.0 × 104 4.0 ± 0.6 
TM 
9.6 ± 0.5 × 
104 2.00 ± 0.19  4.5 ± 5.0 × 104 5.7 ± 0.7 
4.2. Bulk refractive index and temperature sensitivity 
The bulk refractive index sensitivity and LOD of the MRR with highest Q were characterized 
by flowing deionized water and NaCl solutions over the device while repeatedly recording the 
transmission spectra. Figure 5(a) shows the shift of the resonance peak for various NaCl 
concentrations. Due to the higher refractive index of the top cladding, the neff increases, 
resulting in a positive shift of the resonance wavelength. The real-time response was recorded 
by monitoring the resonance wavelength shift over time while flowing different liquids and 
can be seen in Fig. 5(b). The drops of the resonance wavelength shifting down to the water 
baseline signal correspond to switching between the different NaCl solutions. Figure 5(c) 
shows the determined bulk refractive index sensitivities, which amount to 70.8 ± 0.6 nm/RIU 
and 102.3 ± 0.5 nm/RIU for TE and TM polarizations, respectively. Due to the modal field 
being less confined for the TM polarization, its bulk refractive index sensitivity is higher than 
that for TE polarization. 
 
Fig. 5. (a) Shift of resonance wavelength peak for bulk refractive index variation of the water 
flow over the MRR for TM polarization. (b) Real-time monitoring of the shift of the resonance 
wavelength during bulk refractive index sensing for both TE and TM polarization. The flow 
was switched every 3 minutes between deionized water and NaCl solutions with 
concentrations ranging from 0.30 wt% down to 0.05 wt%. The flow rate was 100 µl/min. (c) 
Resonance wavelength shift for variations of the bulk refractive index. (d) Resonance 
wavelength noise during the bulk refractive index experiment for TM polarization. 
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The MRR is subjected to wavelength and intensity noise, which impose an uncertainty on 
the determination of the resonance wavelength. This can be lowered by repeatedly acquiring 
spectra and fitting their resonance wavelengths, followed by averaging the results [49]. For 
the bulk refractive index sensing the uncertainty is the standard deviation of the fitted 
resonance wavelength during a time interval of 2 minutes, or 15 repeated measurements and 
is shown in Fig. 5(d). This time corresponds with the duration of the MRR exposure time to 
the liquid to be sensed. The standard deviation in the resonance wavelength was determined 
and yielded a noise of 3σ = 0.11 pm for TM polarization. Combining the measured bulk 
refractive index sensitivities with the measured detection noise yields a highest LOD of 1.1 × 
10−6 RIU for TM polarization, a value similar to the best reported results achieved with SOI 
and silicon nitride MRR refractive index sensors [16,23]. 
The MRR’s temperature sensitivity was determined by monitoring the shift of the 
resonance wavelength over time while increasing the stage temperature, as shown in Figs. 
6(a) and 6(b). Temperature sensitivities of 8.1 ± 0.1 pm/K and 4.3 ± 0.1 pm/K were measured 
for TE and TM polarizations, respectively. The latter is lower since more modal power 
resides in the aqueous top cladding that has a negative thermo-optic coefficient [47]. A lower 
temperature sensitivity is desirable for a lower resonance wavelength noise and drift. The 
measured higher bulk refractive index sensitivity combined with the lower temperature 
sensitivity motivated to operate the MRR in TM polarization for the biosensing experiments. 
 
Fig. 6. (a) Real-time monitoring of the shift of the resonance wavelength while varying the 
stage temperature for both TE and TM polarized light. Deionized water was flown over the 
MRR at a rate of 100 µl/min. (b) Resonance wavelength shift as function of the stage 
temperature. 
4.3. Cancer biomarker detection in urine 
Figure 7(a) shows all the steps of the biosensing experiment and the real-time monitoring of 
antibody immobilization and protein recognition events. The first phase consists of a washing 
step with PBS until a stable baseline was obtained. The second phase is the coating of the 
MRR surface with the anti-S100A4 monoclonal Ab at 50 µg/ml in PBS. After 20 min, a 
stable baseline was observed, indicating that no more binding events occur and that the MRR 
surface is saturated with Ab capture probes. The subsequent washing step with PBS removes 
all the non-covalently bound Ab. The lack of a considerable resonance wavelength shift here 
indicates that the Ab is strongly bound to the MRR surface. The third phase consists of a 
blocking step with BSA to prevent nonspecific adsorption. The washing step showed just a 
small net shift, confirming that most of the biosensor surface was covered during the Ab 
immobilization. Then, the biosensor was exposed to a sample of pooled urine without 
rhS100A4 protein. A large resonance wavelength shift due to the difference in bulk refractive 
index between urine and PBS was observed. Finally, the fifth phase introduces the urine 
containing the protein biomarkers. 
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The biosensing assay was carried out with urine samples containing known concentrations 
of rhS100A4 ranging from 3000 nM down to 3 nM. Figure 7(b) shows the response of the 
biosensor to different concentrations of the protein. For visibility, the two highest 
concentrations tested were omitted (400 and 3000 nM). After 8 minutes, the total wavelength 
shift was recorded and plotted as function of biomarker concentration in Fig. 7(c). As a 
general trend for all concentrations, it can be observed that the resonance wavelength shifts to 
higher values due to protein binding to the Ab, with higher concentrations corresponding with 
larger total shifts. Furthermore, for the highest concentrations the total shift saturates, 
indicating that equilibrium between binding and disassociation of the proteins to the Ab has 
been achieved. 
For the biosensing experiment in urine, the uncertainty is defined as the total resonance 
wavelength drift during the 8 minutes measurement interval of a blank urine sample, as 
shown in Fig. 7(d). In this case, a drift of ~0.05 pm/min was measured, which is most likely 
due to some non-specific binding or buildup of material on the MRR. In this case, the LOD is 
the smallest protein concentration that yields a total shift that is equal to or larger than three 
times this drift (i.e., 1.2 pm). At an rhS100A4 protein concentration of 3 nM, a total 
resonance wavelength shift of 1.43 pm was measured after 8 minutes of measurement, 
establishing the limit of detection of this system at 3 nM, which lies within the clinically 
range demonstrated by Turnier et al. 
Figure 7(e) shows the selectivity test of the biosensing procedure by performing two 
control experiments. First, 400 nM rhS100A4 protein was flown over a MRR without Ab 
immobilized on its surface. The resulting resonance wavelength shift (6.3 pm) is ~10 times 
smaller than that of a MRR with Ab immobilized for the same protein concentration (59.9 
pm). Second, a urine sample containing neutravidin protein, which should not be bound to the 
Ab upon molecular recognition, was flown over the biosensor. Indeed, the resulting resonance 
wavelength shift for the sample containing neutravidin was 20 times smaller (3.1 pm) than 
that for the rhS100A4 protein. These results indicate that our biosensing platform using anti-
S100A4 antibodies is highly selectively in sensing hrS100A4 proteins. 
The platform described herein, is sensitive and selective for hrS100A4 protein detection in 
undiluted urine. By immobilizing other selective probes onto the surface, it is possible to 
confer target-specific binding properties and thus develop a multiplexed system to detect 
several biomarkers with a small volume of sample and within a few minutes. Future work will 
focus on developing a multiplexed platform to obtain multiple clinically relevant 
measurements from a single sample. 
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Fig. 7. (a) MRR sensorgram. The MRR was addressed with PBS 10 mM (I), anti-S100A4 
antibody at 50 µg/ml (II), BSA 1% in PBS (III), urine (IV), and rhS100A4 at 25 nM in urine 
(V). The flow rate was 100 µl/min. (b) Binding of rhS100A4 to the antibodies immobilized 
onto the MRR’s surface. The initial bumps results from the dynamics of the flow system. (c) 
Resonance wavelength shift as function of rhS100A4 concentration. (d) Resonance wavelength 
noise for a blank urine sample. (e) Selectivity assay for anti-S100A4 antibody in urine. Control 
I: rhS100A4 at 400 nM, without antibody coated on the surface. Control II: neutravidin at 400 
nM in urine. 
5. Conclusion 
To conclude, the Al2O3 photonic platform developed here appears as a very promising 
biosensor platform. Its bulk refractive index sensitivity of ~100 nm/RIU and LOD of ~10−6 
RIU are comparable with the more mature SOI and silicon nitride technologies. A robust 
surface functionalization protocol was developed that permits a good coverage of the surface 
of the Al2O3 sensor with antibodies. The label-free detection of 3 nM of the rhS100A4 
protein, associated with cancer disease, was demonstrated in whole urine without the need of 
neither sample pre-treatment nor signal amplification steps and within less than ten minutes. 
Also, MRR offer real-time monitoring capacity in contrast with commercial immunoassay 
kits that only offer endpoint readout. The particular attributes of rapid response, small volume 
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of sample, simple format and easy to use, lend Al2O3 biosensing platform to be used as a 
point-of-care device with real patient samples in clinical environments. 
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